IP Verse

Dosing Regimen For A Selective S1p1 Receptor Agonist - EP3256125

PATENT ANALYSIS

Patent Details

Grant Date
Jan 26, 2022
Company
ACTELION PHARMACEUTICALS LTD
Oppositions

STADA ARZNEIMITTEL AG

TEVA PHARMACEUTICAL INDUSTRIES LTD.

More patents of Actelion Pharmaceuticals Ltd

EP3256125

EP3592391

EP3300729

Want to monitor this patent?

Feel free to send us a message here and we will get back to you